Director, Investor Relations & External Communications

Philadelphia, Pennsylvania (Remote)

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. The company recently presented final phase 1/2 data for rese-cel in myositis and expects to initiate the pivotal myositis trial this year. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com
and connect with us on LinkedIn.

At Cabaletta, we are driven by the shared mission of developing cures, where a patient’s own cells are used to fight disease. We are building a culture grounded in the knowledge that successful cures can be achieved for patients if every member of the Cabaletta is focused on the success of the team. To nurture this, we make an active commitment to the well-being and continuous growth of each employee who joins the team. In this way, we are not only working to improve the lives of patients, but of everyone involved.  And we’re proud that for 3 years in a row, we’ve been nationally recognized by Great Place to Work and Fortune as one of the Top 10 Best Small/Medium Workplaces in Biopharma!

About the Position:

The Director, Investor Relations & External Communications will play a critical role in shaping how Cabaletta Bio is understood by the investment community and external stakeholders during a period of significant value creation.

Reporting to the Chief Financial Officer, with a dotted line to the Chief Business Officer, this individual will lead the development and execution of Cabaletta Bio’s investor relations and external communications strategy. This highly visible role will partner closely with executive leadership to ensure that our scientific progress, clinical milestones, and long-term vision are translated into clear, compelling, and credible narratives.

We are seeking a strategic and hands-on leader who is equally comfortable engaging with investors and building internal alignment across functions, and who brings a strong understanding of the complexities and opportunities inherent in autologous cell therapy.

Responsibilities:

Strategic Leadership

Develop and execute an integrated investor relations and external communications strategy aligned with Cabaletta Bio’s corporate milestones, including BLA submission and commercialization readiness.
Partner with executive leadership to shape, refine, and consistently communicate Cabaletta Bio’s investment thesis and corporate narrative.
Serve as a trusted advisor to the CFO, CBO, and CEO on messaging, positioning, and engagement with the investment community.
Build scalable processes and infrastructure to support Cabaletta Bio’s evolution into a commercial-stage organization.

Investor Relations

Serve as a primary point of contact for investors and analysts, fostering strong, long-term relationships across the investment community.
Lead preparation of earnings materials, investor presentations, and key external communications.
Support capital markets activities, including financings, investor targeting, and roadshows.
Monitor market dynamics, peer landscape, analyst coverage, and investor sentiment to inform strategy and leadership decision-making.
Provide ongoing insights to executive leadership regarding valuation drivers and investor expectations.

Track and schedule investor interactions and provide insights into future interactions.

External Communications

Own and ensure consistency of messaging across all external channels, including press releases, investor materials, and corporate content.
Translate complex clinical, regulatory, and scientific developments into clear, accessible, and compelling narratives.
Support communications related to clinical milestones, regulatory interactions, and business development activities.
Partner with external agencies to enhance Cabaletta Bio’s visibility and ensure alignment of messaging.
Support executive visibility, conference participation, and thought leadership opportunities.

Cross-Functional Collaboration

Work closely with Clinical, Regulatory, R&D, Commercial, and Business Development teams to ensure alignment between internal progress and external messaging.
Support preparation for investor meetings, earnings calls, and key external engagements.
Ensure consistent, thoughtful communication during critical inflection points, including clinical readouts and regulatory milestones.

Qualifications:

Bachelor’s degree required; advanced degree (PhD, MD, MBA, or related) preferred.
10+ years of experience in investor relations, equity research, investment banking, or corporate communications within biotech or life sciences.
Direct experience in autologous cell therapy required, with a strong appreciation for the development, manufacturing, and commercialization complexities.
Experience supporting companies through late-stage clinical development, BLA/NDA submission, or commercialization preferred.
Strong understanding of biotech capital markets, investor expectations, and value drivers.
Demonstrated ability to synthesize complex scientific and clinical information into clear, compelling messaging.
Experience engaging with institutional investors, analysts, and executive leadership.
Ability to operate effectively in a fast-paced, collaborative, and evolving environment.

Our name – Cabaletta – is derived from the operatic term that represents a rapid, repetitive, and technically challenging section of an operatic aria, where the second act is designed to showcase the skills of the lead singer. Analogously, Cabaletta Bio strives to achieve rapid and repetitive product development, building on our indication prioritization and biologic platform that targets the driver of specific autoimmune diseases without the need for long-term immunosuppression.

For more information, please visit  https://www.cabalettabio.com/join-our-crew

Our most important asset is our people, and we offer competitive benefits, PTO, and stock option plans.

Cabaletta Bio is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law.